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Abstract
Background: The highly pathogenic avian influenza (HPAI) H5N1 virus continues to cause disease in poultry and humans.
The hemagglutinin (HA) envelope protein is the primary target for subunit vaccine development.
Methodology/Principal Findings: We used baculovirus-insect cell expression to obtain trimeric recombinant HA (rHA)
proteins from two HPAI H5N1 viruses. We investigated trimeric rHA protein immunogenicity in mice via immunizations, and
found that the highest levels of neutralizing antibodies resulted from coupling with a PELC/CpG adjuvant. We also found
that the combined use of trimeric rHA proteins with (a) an inactivated H5N1 vaccine virus, or (b) a recombinant adenovirus
encoding full-length HA sequences for prime-boost immunization, further improved antibody responses against
homologous and heterologous H5N1 virus strains. Data from cross-clade prime-boost immunization regimens indicate
that sequential immunization with different clade HA antigens increased antibody responses in terms of total IgG level and
neutralizing antibody titers.
Conclusion/Significance: Our findings suggest that the use of trimeric rHA in prime-boost vaccine regimens represents an
alternative strategy for recombinant H5N1 vaccine development.
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Introduction
Influenza viruses trigger seasonal disease epidemics and
potential pandemics, both with mild-to-severe consequences for
human and poultry populations [1]. Influenza type A virus, a
member of the Orthomyxoviridae family, consists of single-stranded
eight-segment negative-sense genomic RNAs, helical viral ribonu-
cleoprotein (RNP) complexes (RNA segments NP, PB2, PB1 and
PA), three viral envelope proteins (hemagglutinin [HA], neur-
aminidase [NA], and M2 ion channel), and a maxtir (M1) protein.
Influenza A viruses are further classified into 16 HA (H1–H16)
and 9 NA (N1–N9) serotypes based on the antigenic characteristics
of HA and NA envelope glycoproteins [2].
In aquatic birds, the 16 HA and 9 NA influenza A virus
subtypes are not disease triggers [2]. In contrast, highly pathogenic
avian influenza (HPAI) viruses such as H5N1, H7N3, H7N7 and
H9N2 can result in severe diseases with mortality in poultry, and
occasionally in human populations [3]. H5N1 was the main virus
in the first human outbreak in 1997; it emerged again in 2003, and
has continued to cause disease in poultry and humans. Between
1997 and 2010, human HPAI H5N1 resulted in rare and sporadic,
but often severe and fatal human infections in Asia, the Middle
East, Eastern Europe, and Africa. The mortality rate for the 520
cases reported during that period was 59% [4].
HA, a major envelope glycoprotein, is a major target for the
development of influenza vaccines. Recombinant HA (rHA)
proteins have been developed as a subunit vaccine against H5N1
infection. The rHA vaccine approach is an attractive alternative for
vaccine manufacturing because itremovestheneed foregg-basedor
cell-based H5N1 influenza virus vaccine production, thus eliminat-
ing the associated requirement for 2+ or 3 biosafety levels for
facilities and equipment. Several research teams have reported that
neutralizing antibody titers against the H5N1 virus can be induced
inmice,chickens,andferretsvia rHAproteinsproduced from insect
cells [5,6,7], mammalian cells [7,8,9], plant cells [10,11] and E. coli
[6,12,13,14,15]. For this study we used baculovirus-insect cell
expression to obtain rHA proteins from two HPAI H5N1 strains:
KAN-1 and Anhui. The rHA proteins were engineered to form
trimers usingadditionalsequencesfromtheleucinezipperGCN-pII
[16] fused at the C-terminal end. Mice immunized with trimeric
rHAproteinscoupled withAlum,CpG,Alum/CpG, PELC[17],or
PELC/CpG are capable of eliciting HA-specific IgG responses and
neutralizing antibodies. In addition, we combined trimeric rHA
proteins with an inactivated H5N1 vaccine virus, or recombinant
adenovirus (rAd-HA) encoding full-length HA sequences of HPAI
H5N1 viruses as part of a prime-boost immunization strategy aimed
at enhancing elicited antibody responses against homologous and
heterologous H5N1 virus clades.
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Trimeric rHA protein construction, purification, and
characterization
We used a baculovirus-insect cell expression system to generate
three truncated forms of rHA (Tr1, Tr2, Tr3), with the transmem-
brane and cytoplasmic domains at the C terminus of full-length HA
sequences replaced with the GCN4pII sequence KQIEDKIEEILS-
KIYHIENEIARIKKLIGEV and a His tag (Fig. 1). The polybasic
cleavage site between HA1 and HA2 was changed from
PQRRRKKRG to PQTRG to prevent unwanted cleavages in
baculovirus-infected insect cells. We obtained rHA proteins from the
culture supernatants of Sf9 cells infected with the recombinant
baculoviruses. The three truncated rHA forms of the KAN-1 and
Anhui strains were purified using Ni-NTA agarose chromatography
(Fig. 2A–B). Hemagglutination of the three forms was tested for using
turkey red blood cells; results indicate that the Tr1 proteins retained
the highest HA titers compared to the Tr2 and Tr3 forms (Fig. 2C–
D). We also treated the Tr1 rHA proteins of KAN-1 and Anhui
strains with trypsin, revealing HA protein cleavage into HA1 and
HA2 subunits (Fig. 3A–B). KAN-1 and Anhui rHA trimeric
structures were evaluated by treatment with ethylene glycol-bis
(EGS), a homobifunctional and cleavable cross-linking reagent
previously used to analyze the trimeric form of HIV-1 gp120 [18].
According to our results, Tr1 monomers were cross-linked with a
dimer, and then with a trimer, indicating that most of the rHA
proteins of the KAN-1 and Anhui strains are trimers (Fig. 3C–D).
Trimeric rHA protein immunogenicity
To determine the immunogenicity of KAN-1 and Anhui trimeric
rHA proteins, we intramuscularly immunized a group of BALB/c
mice with 15 mg rHA per mouse, coupled with an adjuvant of Alum
(300 mg/dose), CpG oligodeoxynucleotides (10 mg/dose), Alum/
CpG, PELC (10%), or PELC/CpG. Two immunizations were given
over a 3-week period. Anti-sera were collected 2 weeks after the
second immunization, and used to evaluate elicited antibody
responses. According to results from an ELISA coated with the
trimeric rHA proteins of KAN-1 (Fig. 4A) or Anhui (Fig. 4B), mice
immunized with either rHA protein plus the PELC/CpG adjuvant
produced the highest levels of HA-specific total IgG titers.
Immunization with trimeric rHA proteins plus PELC or PELC/
CpG adjuvants also induced higher IgG1 and IgG2a subtype titers
compared to trimeric rHA proteins plus Alum, CpG, or Alum/CpG
(Fig. 4C–D). Neutralization curves against KAN-1 or Anhui H5pp
indicate that immunization with the trimeric rHA proteinsplusany of
the adjuvant formulations that were investigated in this study induced
neutralizing antibody responses in a dose-dependent manner
(Fig. 5A–B). Corresponding log (ID-50) values against KAN-1
H5pp and Anhui H5pp are shown in Figures 5C–D. According to
these results, trimeric Anhui rHA proteins were more immunogenic
than those of the KAN-1 strain for all of the investigated adjuvant
formulations. The PELC/CpG adjuvant was the mosteffective of the
four adjuvant formulations in terms of enhancing antibody responses
in mice immunized with trimeric rHA proteins.
Combined use of trimeric rHA proteins with an
inactivated or adenovirus vaccine for prime-boost
immunization
We also evaluated the combined use of trimeric rHA proteins
coupled with the PELC/CpG adjuvant, using either inactivated
H5N1 NIBRG-14 virus, or a recombinant adenovirus encoding the
full-lengthHAgene ofKAN-1(H5N1clade 1)orAnhui(H5N1clade
2.3.4). Mice immunized with the inactivated NIBRG-14 virus
followed by a booster with a trimeric rHA protein elicited slightly
higher totalIgGtiters compared to micereceiving double-NIBRG-14
virus immunizations (Fig. 6A–B). Priming with rAd-HA (Anhui)
followed by a booster with a trimeric rHA protein (KAN-1) resulted
in the highest anti-Anhui rHA total IgG titer (Fig. 6B). Compared to
mice receiving a double-dose of inactivated NIBRG-14, increases of
IgG1 subtypes and (to a lesser degree) IgG2a subtypes were observed
in mice receiving an initial immunization of inactivated NIBRG-14,
rAd-HA (KAN-1), or rAd-HA (Anhui) followed by a booster with
KAN-1 or Anhui trimeric rHA proteins (Fig. 6C–D). These
combinations produced more balanced Th1 and Th2 responses
compared to inactivated NIBRG-14 virus immunization with a
trimeric HA protein booster, or two doses of inactivated NIBRG-14.
Neutralization H5pp assays were used to determine neutralizing
antibody titers elicited by the use of trimeric rHA proteins in
combination with inactivated NIBRG-14 or rAd-HA versus dual-
dose NIBRG-14 virus immunizations. According to our results, all of
these prime-boost immunization combinations induced dose-inde-
pendent neutralizing antibody responsesagainstKAN-1(Fig. 7A) and
Anhui (Fig. 7B). The ID-50 values were higher for the inactivated
NIBRG-14 virus plus trimeric rHA protein booster than for the two-
dose inactivated NIBRG-14 virus immunization against the same or
different H5N1 HA clade (Figs. 7C–D). An Anhui rHA protein
booster induced more neutralizingantibody titers thanaKAN-1rHA
protein booster following inactivated NIBRG-14 virus priming, but
the difference was not statistically significant. Compared to two-dose
inactivated NIBRG-14 virus immunization, priming with KAN-1 or
Anhui rHA protein plus an inactivated NIBRG-14 virus booster
resulted in either a slower increase or outright reduction of
neutralizing antibody titers against both the homologous (clade 1)
and heterologous (clade 2.3.4) strains of H5N1 viruses. Priming with
KAN-1 rAd-HA followed by an Anhui rHA protein booster resulted
in the highest ID50 values against KAN-1, but the difference was not
statistically significant compared to two-dose inactivated NIBRG-14
virus immunization (Fig. 7C). Priming with either rAd-HA (KAN-1
or Anhui) followed by a booster with KAN-1 or Anhui rHA protein
elicited stronger neutralizing antibody responses against the H5N1
Anhuiclade(2.3.4)thantwodosesofinactivatedNIBRG-14(Fig.7D).
Priming with Anhui rAd-HA followed by a KAN-1 rHA protein
booster resulted in the highest ID50 values against Anhui (Fig. 7D).
The use of different HA antigen clades in adenovirus vector-primed
and recombinant protein booster immunizations further enhanced
Figure 1. HA protein constructs. Vectors encoding three truncated
forms of soluble trimeric HA (Tr1, Tr2, Tr3) were constructed using the
baculovirus expression vector pFastBac 1. In these constructs, the
polybasic cleavage site between HA1 and HA2 was changed from
PQRRRKKRG to PQTRG to prevent cleavages. Transmembrane and
cytoplasmic domains at the C terminus of full-length HA were deleted
and replaced with a leucine zipper GCN4-pII sequence (MKQIEDKIEEILS-
KIYHIENEIARIKKLIGEV) for trimerization. An His-tag was added for
purification.
doi:10.1371/journal.pone.0020052.g001
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H5N1 virus strains.
Discussion
Trimeric rHA proteins were prepared using a GCN4-pII
leucine zipper sequence, and functionally expressed using a
baculovirus-insect cell expression system. Trimeric rHA protein
immunogenicity was increased via coupling with a PELC/CpG
adjuvant. We found that compared to dual-dose inactivated
vaccine immunization, the combined use of trimeric rHA proteins
with an inactivated NIBRG-14 vaccine virus or rAd-HA vaccine
for prime-boost immunization enhanced antibody responses
against homologous and heterologous H5N1 virus strains.
Trimeric HA protein expression of avian and human influenza
viruses has been reported for the trimerization sequences of a
GCN4-pII leucine zipper [8,16,19,20,21,22,23] and the foldon
domain of bacteriophage T4 fibritin [7,9,24,25]. Foldon-derived
oligomerization sequences have been described as forming high-
molecular-weight oligomers in addition to trimers [7]. Here we
used a GCN4-pII leucine zipper sequence that specifically triggers
trimerization, rather than GCN4-pIL sequences for dimerization
or GCN4-pLI sequences for tetramerization [16,21]. According to
our results, the KAN-1 and Anhui rHA proteins were predom-
inantly trimeric, which is consistent with previous reports on rHA
protein expression for the H3N2 [22] and H5N1 viruses [8].
We constructed three truncated forms of trimeric rHA proteins
(Tr1, Tr2, Tr3) from the ectodomain HA sequences of two HPAI
H5N1 viruses, KAN-1 and Anhui. Our data indicate that (a) Tr1
served as the HA ectodomain (aa 1 to 531); (b) Tr2 (aa 1 to 524)
was shorter in length compared to Tr1, with sequences deleted
between the transmembrane domain and the bromelain cleavage
site; and (c) Tr3 (aa 1 to 517) was the shortest of the trimeric rHA
proteins terminated at the bromelain cleavage site. The high-to-
low order of HA titers in the three truncated forms was Tr1 . Tr2
. Tr3 (Fig. 2C–D). According to an earlier study, the 14
additional amino acids between Tr1 (terminated at the trans-
membrane domain) and Tr3 (terminated at the bromelain
cleavage site) do not affect neutralizing antibody response in mice;
however, Tr3 immunogenicity is greatly reduced by NA co-
expression [7]. In contrast, the co-administration of rHA and
recombinant NA proteins from the 2009 pandemic H1N1 virus
resulted in enhanced HA-specific immune response in ferrets [21].
Monomeric HA proteins are not highly immunogenic in humans
[26,27]. Enhanced rHA protein immunogenicity can be achieved
by coupling with adjuvants such as Stimune [8], Titermax [15],
Freund [11], Polygen [11], BAY98-7089 [11], and Ribi [7]. For the
present study we investigated the adjuvant formulations Alum,
CpG, Alum/CpG, PELC, and PELC/CpG to determine their
respective effects on trimeric rHA protein immunogenicity. Our
results indicate that (a) PECL, an adjuvant recently developed for
inactivated NIBRG-14 [17], was more potent than Alum; and (b)
CpG resulted in the highest levels of neutralizing antibodies in mice
via trimeric rHA immunization. We used 15 mg of trimeric KAN-1
or Anhui rHA protein for mouse immunizations, resulting in the
elicitation of anti-H5N1 neutralizing antibody response with a log
ID50 value of 2.5 (KAN-1) or 4.2 (Anhui) (Fig. 5C–D). Similar
results have been reported for 20 mg of trimeric rHA protein
(human cell expression) coupled with Ribi [7] or Alum [28]
adjuvant for two-dose mouse immunizations. The corresponding
log ID50 values in these studies were 3.3 (Ribi) and 2.1 (Alum).
However, a more recent report indicates that only 2 mg of trimeric
Figure 2. HA protein purification. Trimeric HA proteins were obtained via recombinant baculoviruses encoding H5N1 HA sequences from culture
supernatant. Three truncated forms each of HA proteins from KAN-1 (A) and Anhui (B) strains were purified using metal affinity chromatography with
Coomassie blue staining (left). Purified proteins were confirmed by western blotting (right) using anti-6xHis antibody. Purified HA proteins from KAN-
1 (C) and Anhui (D) strains were digested with trypsin to confirm that the HA with a cleavage site mutation could be cleaved into HA1 (detected by
polyclonal anti-H5HA antibodies, left) and HA2 (detected by polyclonal anti-6xHis antibodies, right).
doi:10.1371/journal.pone.0020052.g002
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adjuvant) in dual-dose immunizations was sufficient for inducing
anti-H5N1 protection in mice [8].
Prime-boost immunization with inactivated A/Vietnam/
1203/2004 (clade 1) followed by inactivated A/Indonesia/05/
2005 (clade 2.1) has been reported as inducing a potent
neutralizing antibody response against heterologous H5N1 virus
clades [29,30]. We therefore examined the combined use of
trimeric rHA proteins with inactivated NIBRG-14 vaccine virus
as part of a prime-boost immunization strategy to enhance
antibody responses against both homologous and heterologous
H5N1 virus clades. According to our findings, significantly
higher IgG1 titers (as opposed to IgG2a titers) were elicited,
suggesting that enhanced Th2 responses were triggered by the
inactivated virus-prime and trimeric rHA protein-booster
regimen. Following priming with inactivated NIBRG-14, a
trimeric Anhui rHA protein (clade 2.3.4) booster resulted in
higher neutralizing antibody titers compared to a KAN-1 rHA
protein (clade 1) booster, but did not always result in increased
IgG titers. Neutralizing antibody responses to homologous and
heterologous H5N1 virus clades increased to a greater extent
when Anhui trimeric rHA was used as a booster instead of
KAN-1 trimeric rHA or inactivated NIBRG-14. The fact that
the Anhui strain is more immunogenic than that of the KAN-1
strain was also demonstrated in immunizations using trimeric
rHA proteins with any of the investigated adjuvant formula-
tions. The HA protein sequences between KAN-1 and Anhui
are highly conserved, with 94.4% amino acid identity or 96.6%
amino acid similarity. The region near the 130 loop has been
demonstrated as a Ca2 antigenic site in H1HA [31,32], and
s e v e r a lm o n o c l o n a la n t i b o d i e sh a v eb e e ni s o l a t e dt oc o n f i r m
Ca2 antigenicity in H5HA [33,34]. There are two positive-
charge residues (R
139 and K
140) near the 130 loop of the
receptor-binding domain in KAN-1 HA, but not in Anhui HA;
these residues may explain the antigenic differences between the
two.
We also found that the combination of trimeric rHA protein
and recombinant adenovirus vector as a prime-boost strategy
elicited more potent neutralizing antibody responses against
homologous and heterologous H5N1 virus strains. Specifically,
we investigated KAN-1 rAd-HA or Anhui rAd-HA vaccination
followed by a booster of either KAN-1 or Anhui trimeric rHA
protein. The sequential HA antigen clade regimen of an Anhui
rAd-HA prime and trimeric KAN-1 rHA booster resulted in
increased antibody responses in terms of total IgG and
neutralizing antibody titers. This result is consistent with other
findings that sequential immunization with different H3HA is
capable of eliciting significant amounts of broadly neutralizing
H3N2 antibodies [35]. However, our results from prime-boost
immunizations using different clades of HA antigens to elicit
higher neutralizing antibody responses do not agree with
previously reported results for the original antigenic sin response
of influenza viruses [36]. Further effort is required to investigate
the mechanisms through which sequential immunization with
different HA antigens can enhance neutralizing antibody response.
The combined use of trimeric rHA in prime-boost vaccine
regimens may represent an alternative strategy for recombinant
H5N1 vaccine development.
Figure 3. HA protein characterization. Trimers of the Tr1 forms of HA proteins from KAN-1 (A) and Anhui (B) strains were examined using the
homobifunctional and cleavable cross-linking reagent ethylene glycol-bis (EGS). Tr1 monomers were cross-linked into a dimer and then into a trimer
as EGS concentration increased. Turkey red blood cells were used to test the hemagglutination activity of purified KAN-1 (C) and Anhui (D) HA. Of the
three truncated forms, Tr1 displayed the highest HA titer level.
doi:10.1371/journal.pone.0020052.g003
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Recombinant H5HA protein construction and purification
Soluble HA proteins were constructed using the HA cDNA
sequences of H5N1 A/Thailand/1(KAN-1)/2004 and A/Anhui/
1/2005. The A/Thailand/1(KAN-1)/2004 gene was kindly
provided by Prasert Auewarakul of Siriraj Hospital at Mahidol
University, Thailand. The A/Anhui/1/2005 gene was purchased
from Mr. Gene; synthesized sequences were based on the NCBI
GenBank accession number DQ371928. The multibasic protease
cleavage site between HA1 and HA2, PQRERRRKKRG, was
mutated to PQRETRG to retain the uncleaved protein. To obtain
trimeric HA proteins, we fused the HA C-terminal sequence with
the trimeric GCN4 sequence in front of a thrombin cleavage site,
ending with a His-tag to facilitate purification. For large-scale
production, Sf9 cells (Invitrogen) were grown in 600 ml SF900-II
serum-free medium (Invitrogen) at a cell density of 2610
6 cells/ml,
then infected with a specific recombinant baculovirus at 3 MOI.
Infected cells and culture supernatants were collected 48 h post-
infection. Trimeric HA protein expression was determined with
SDS-polyacrylamide gels and Western blots using anti-H5HA
antibodies (Abcam). Trimeric HA purification was performed with
nickel-chelated affinity chromatography (Pierce Protein).
Cross-linking procedures
Ethylene glycol bis (50 mM) (Sigma) was dissolved in dimethylsulf-
oxide and diluted intoproteinsolutionsatconcentrationsof 0.25, 1,2,
5 and 10 mM. Samples were held for 30 min on ice; reactions were
stoppedby theadditionof50 mMglycineprior toincubationat37uC
for 30 min. Cross-linked samples were analyzed by SDS-PAGE.
Hemagglutination assays
Purified recombinant HA (100 mg/ml) was serially diluted 2-
fold in V-bottom 96-well plates. Equal volumes of 0.05% turkey
red blood cells (approximately 4610
7 cells/50 ml) (Animal
Technology Institute, Taiwan) were added to each well. Plates
were covered and held at room temperature for 45 min. HA titers
were determined by the reciprocal of the last dilution containing
agglutinated turkey red blood cells.
Inactivated virus and recombinant adenovirus
preparations
pENTR (Invitrogen) was used as a transfer vector to create
adenoviral vectors containing HA from the H5N1 influenza virus
strains A/Thailand/1(KAN-1)/2004 and A/Anhui/1/2005. A full-
length coding region of the HA gene was inserted into the transfer
vector, followed by positive selection with kanamycin+ LB plate. LR
Figure 4. Antibody responses elicited by HA proteins in immunized mice. BALB/c mice were intramuscularly inoculated with two doses of
HA protein (15 mg) coupled with one of five adjuvant formulations. Total IgG antibody responses in mice immunized with KAN-1 (A) or Anhui (B) HA
were evaluated 2 weeks following the second immunization. HA protein immunization coupled with PELC/CpG adjuvant induced the largest amount
of IgG titers. IgG subclasses were detected using ELISA. PELC and PELC/CpG adjuvants coupled with KAN-1 (C) or Anhui (D) HA induced higher levels
of IgG1 and IgG2a subtypes compared to the Alum or CpG adjuvants. All values are expressed as geometric mean with a standard error of the mean
of five mice per group. Asterisk (*) indicates a statistically significant difference compared to the PELC/CpG group (p,0.05, Student t test).
doi:10.1371/journal.pone.0020052.g004
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recombination between the pENTR vector containing the HA gene
and the rAd vector pAd/CMV/V5-DEST (Invitrogen). Following
Pac I digestion, the rAd vector was transfected into HEK293A cells
(Invitrogen); P1 recombinant adenovirus encoding HA was produced
7,10 days post-transfection, and then further amplified to produce a
P2 virus; virus titer was determined by plaque assay.
H5N1-inactivated NIBRG-14 vaccine, derived from avian
influenza virus A/Vietnam/1194/2004 [17], was kindly
provided by the Vaccine Research and Development Center
(VRDC) of the Taiwan National Health Research Institutes
(NHRI). The virus was propagated at the Center in serum-
free media (Cesco, Taiwan) using MDCK cells (BCRC,
FIRDI, Taiwan) grown in roller bottles. The virus was
inactivated by 0.1% formalin at 37uC for 24 hr. HA content
of the formalin-inactivated virus was determined by single-
radial diffusion assays, using standard antigens and antiserum
from NIBSC.
Adjuvant preparation
We used the CpG ODN sequence 59-ATC GAC TCT CGA
GCG TTC TC-39 with all phosphorothioate backbones (kindly
provided by Ken Ishii of Osaka University). Aluminum phosphate
(Alum) (also from the VRDC of the Taiwan NHRI) was given
300 mg doses in acidic media (pH=6). As previously described,
PELC is a squalene W/O/W nanoemulsion adjuvant [17]. Briefly,
120 mg of PEG-b-PLACL, 0.8 mL of aqueous solution, and
1.1 mL of oily solution consisting of squalene (Sigma-Aldrich) and
SpanH85 (Sigma-Aldrich) were emulsified at 6,000 rpm for 5 min
and stored at 4uC before use.
Mouse immunization
Female BALB/c mice (6,8 weeks old) were immunized with
15 mg purified recombinant HA protein or inactivated NIBRG-14
virus (HA content 0.5 mg) diluted in 50 ml phosphate-buffered
saline (PBS, pH 7.4), and mixed with 50 ml of the adjuvant being
tested: 10 mg CpG ODN; 300 mg alum with 10 mg CpG; 10%
PELC; or 10% PELC with 10 mg CpG. Immunizations were given
by intramuscular injection at the beginning of week 0 and at the
end of week 3. Blood was collected and serum isolated 14 days
following the second immunization. All experiments were
conducted in accordance with the guidelines of the Laboratory
Animal Center of National Tsing Hua University (NTHU).
Animal use protocols were reviewed and approved by the NTHU
Institutional Animal Care and Use Committee (approval
no. 09733).
Figure 5. Neutralization against H5 pseudotyped particles in HA-immunized mice. Neutralization antibody titers were measured as
reduction in luciferase activity of the H5HA-pseudotyped particle (H5pp) following the incubation of sera with H5 pseudotyped particles. p24 of H5pp
(10 ng) was incubated with four-fold serial dilutions of serum for 1 h at 37uC and then transferred to MDCK cells. Luciferase assays were performed
48 h later. Dose-dependent neutralization curves were plotted against homologous KAN-1 (A) and Anhui (B) strains. Neutralization titers against
homologous KAN-1 (C) and Anhui (D) strains and standard deviations were calculated using the ID50 program developed by John Spouge of the
National Center for Biotechnology Information, National Library of Medicine, US National Institutes of Health. PELC/CpG elicited the highest levelo f
neutralization titers, and Alum the lowest. Asterisk (*) indicates a statistically significant difference compared to the PELC/CpG group (p,0.05,
Student t test).
doi:10.1371/journal.pone.0020052.g005
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Briefly, 96-well plates were coated with 2 mg/ml of purified
trimeric HA protein. After three washes with PBST, samples were
blocked with 1% BSA in PBS for 30 minutes at room temperature,
followed by three additional washes. The addition of 2-fold serial
dilutions of mouse sera was followed by incubation for 1 hr at room
temperature, followed by another three washes. Anti-HA IgG
antibodies were detected by incubation with peroxidase-conjugated
goat anti-mouse IgG antibodies (Abcam) for 1 hr at room
temperature. After three washes, TMB substrate was added to
develop color, and 2N H2SO4 was added to stop reactions. Plates
were read at 450 nm absorbance; end-point titer was determined as
the reciprocal of the final dilution giving an optical of four-fold
absorbance of negative control. Anti-HA antibody subclasses were
determined by ELISA using anti-IgG1 and anti-IgG2a antibodies.
H5 pseudotyped particle (H5pp) neutralization assays
Influenza lentiviral pseudotyped viruses were generated as
described previously [37]. Briefly, HEK293T cells (BCRC,
FIRDI, Taiwan) were co-transfected with pNL Luc E
2 R
2 and
pcDNA3.1(+) expressing HA from A/Thailand/1(KAN-1)/2004
and A/Anhui/1/2005 strains. Vibrio cholerae neuraminidase
(6.2 mU/ml; Sigma) was added 24 hr post-transfection to release
particles from cells. Culture supernatants were collected and
concentrated 48 hr post-transfection. H5pp titer was determined
by p24 ELISA (Clontech). Neutralizing antibodies were quantified
as reduced luciferase expression level following H5pp transduction
in MDCK cells. MDCK cells (4,000 cells/well) were seeded in 96-
well plates in 100 ml DMEM. The following day, H5pp (10 ng
p24) was incubated with a four-fold serial dilution of anti-sera
(starting dilution 1:64) for 1 hr at 37uCi n6 0ml DMEM. Next,
100 ml of fresh medium was added, and 140 ml of the subsequent
mixture was transferred to the cells. Fresh medium was added
again after 24 hr; luciferase assays were performed 48 hr later via
the direct addition of neolite Luciferase substrate (PerkinElmer).
Neutralization titers and corresponding standard deviations were
determined from neutralization curves using the ID50 program
developed by John Spouge of the National Center for Biotech-
nology Information, National Library of Medicine, US National
Institutes of Health.
Statistical analysis
All results were analyzed using Student’s t tests, with a P value
of ,0.05 indicating statistical significance. Asterisk (*) and
Figure 6. Antibody responses in mice with combined immunizations. Mice were immunized with trimeric KAN-1 or Anhui HA proteins in
combination with inactivated H5N1 vaccine virus NIBRG-14 (clade 1), or a recombinant adenovirus encoding the full-length HA of KAN-1 [rAd(KAN-1)]
or Anhui [rAd(Anhui)]. Total IgG titers from antisera against KAN-1 (A) and Anhui (B) were measured using ELISA; IgG1 and IgG2a against KAN-1 (C)
and Anhui (D) were also determined. Values are expressed as geometric mean with a standard error of the mean of five mice per group. Asterisk (*)
indicates a statistically significant difference compared to the double-dose of inactivated NIBRG-14 group (p,0.05, Student t test). Triangle (h)
indicates a statistically significant difference compared to other immunized groups (p,0.05, Student t test).
doi:10.1371/journal.pone.0020052.g006
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difference. All the experiments were performed at least twice with
similar results.
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